Using A Micro-organism To Make A Protein Or Polypeptide Patents (Class 435/71.1)
-
Patent number: 8624082Abstract: The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: August 30, 2011Date of Patent: January 7, 2014Assignees: Novozymes A/S, Novozymes, Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 8614068Abstract: The present invention provides a novel method for producing biologically functional hepcidin in Pichia pastoris. The invention further provides novel tagged hepcidin, antibodies and their uses in therapy and immunoassays.Type: GrantFiled: August 22, 2008Date of Patent: December 24, 2013Assignees: Hellenic Pasteur InstituteInventors: Avgi Mamalaki, Martha Marinou, Vasiliki Koliaraki
-
Patent number: 8609369Abstract: Promoter regions associated with the Yarrowia lipolytica peroxisomal 2,4-dienoyl-CoA reductase (SPS19) gene are disclosed and have been found to be particularly effective for the expression of heterologous genes in yeast. These promoter regions will be useful for driving high-level expression of genes involved in the production of omega-3 and omega-6 fatty acids.Type: GrantFiled: April 2, 2012Date of Patent: December 17, 2013Assignee: E I du Pont de Nemours and CompanyInventors: Quinn Qun Zhu, Seung-Pyo Hong
-
Patent number: 8609933Abstract: The present invention relates to isolated polypeptides having feruloyl esterase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: November 30, 2009Date of Patent: December 17, 2013Assignee: Novozymes, Inc.Inventors: Doreen Bohan, Kimberly Brown
-
Patent number: 8609932Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: March 6, 2009Date of Patent: December 17, 2013Assignee: Novozymes A/SInventors: Kristian Krogh, Paul Harris
-
Patent number: 8609931Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: September 20, 2010Date of Patent: December 17, 2013Assignee: Novozymes, Inc.Inventors: Kimberly Brown, Paul Harris
-
Patent number: 8603785Abstract: A dihydrolipoamide dehydrogenase (DLD) in a germ is recombined. The new DLD is applied in a solution to degrade an ether bond of an organic polymer. With the present invention, bioremediation is accomplished without secondary pollution of compounds which have environmental hormones.Type: GrantFiled: September 18, 2007Date of Patent: December 10, 2013Assignee: National Central UniversityInventors: Shir-Ly Huang, Yu-Ling Sun
-
Patent number: 8603793Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: May 30, 2012Date of Patent: December 10, 2013Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: 8603781Abstract: The instant invention is drawn to the methods and compositions necessary to provide recombinant proteins with a substantially reduced or eliminated content of norleucine or other non-standard amino acids. Various embodiments of the invention provide for the substantial elimination of the incorporation of non-standard amino acids into recombinant proteins by the co-expression or enhanced expression of a protein (or the enzymatically active portion thereof) capable of degrading norleucine or other non-standard amino acids, including norvaline, beta-methylnorleucine, and homoisoleucine. In certain particular embodiments of the invention, the norleucine is degraded by a glutamate dehydrogenase, a leucine dehydrogenase, a valine dehydrogenase, a phenylalanine dehydrogenase, a glutamate/leucine/phenylalanine/valine dehydrogenase, or an opine dehydrogenase. Also provided are the cells and DNA constructs for carrying out these methods.Type: GrantFiled: September 23, 2004Date of Patent: December 10, 2013Assignee: Monsanto Technology LLCInventors: Gregg Bogosian, Julia P. O'Neil, Hong Q. Smith
-
Patent number: 8603822Abstract: A method for designing a heat-resistant mutant enzyme, the method including the step of reducing a distance between the ?4 helix and the ?6 helix in a protein three-dimensional structure to become smaller than that of a wild type enzyme through deletion, replacement, addition, or insertion of one or several amino acids in the amino acid sequence of the wild type enzyme with respect to tyrosine-dependent short-chain dehydrogenase/reductase.Type: GrantFiled: January 25, 2011Date of Patent: December 10, 2013Assignee: Sony CorporationInventors: Daisuke Yamaguchi, Seiji Yamada, Yoshio Goto, Yuichi Tokita
-
Patent number: 8604277Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: January 28, 2010Date of Patent: December 10, 2013Assignees: Novozymes, Inc., Novozymes A/SInventors: Kirk Schnorr, Michael Rey
-
Patent number: 8603794Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: November 20, 2012Date of Patent: December 10, 2013Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: 8597906Abstract: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.Type: GrantFiled: April 26, 2011Date of Patent: December 3, 2013Assignees: Oxyrane UK Limited, VIB vzw, Universiteit GentInventors: Nico Luc Marc Callewaert, Wouter Vervecken, Karen Jacqueline Marcel De Pourcq, Steven Christian Jozef Geysens, Mouna Guerfal
-
Patent number: 8597901Abstract: Described herein are novel nucleic acids, proteins and methods that can be used to provide new catalysts with desirable traits for industrial processes. In particular, novel reductases isolated from the environment using PCR methods are described.Type: GrantFiled: June 15, 2012Date of Patent: December 3, 2013Assignee: Danisco US Inc.Inventors: Mark Donnelly, William H. Eschenfeldt, Jonathan Trent
-
Patent number: 8586829Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: September 30, 2010Date of Patent: November 19, 2013Assignee: Novozymes A/SInventors: Junxin Duan, Kirk Matthew Schnorr, Wenping Wu
-
Patent number: 8586827Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: September 30, 2010Date of Patent: November 19, 2013Assignees: Novozymes, Inc., Novozymes A/SInventors: Lan Tang, Ye Liu, Junxin Duan, Wenping Wu, Randall Kramer
-
Patent number: 8586828Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: March 6, 2009Date of Patent: November 19, 2013Assignee: Novozymes A/SInventors: Kristian Krogh, Paul Harris
-
Patent number: 8580721Abstract: A solid particulate laundry detergent composition including: (a) substituted cellulosic polymer including carboxymethyl substituent groups, and having a degree of substitution (DS) of at least 0.55, and having a degree of blockiness (DB) of at least 0.35, and having a DS+DB is in the range of from 1.05 to 2.00; (b) amylase with greater than 90% identity to the AA560 alpha amylase endogenous to Bacillus sp. DSM 12649 and including: (i) mutations at one or more of positions 9, 149, 182, 186, 202, 257, 295, 299, 323, 339 and 345; and (ii) mutations at four or more of positions 118, 183, 184, 195, 320 and 458; and (c) laundry detergent ingredients.Type: GrantFiled: March 1, 2011Date of Patent: November 12, 2013Assignee: The Procter & Gamble CompanyInventors: Michelle Meek, Philip Frank Souter, Neil Joseph Lant, Alan Thomas Brooker, Nigel Patrick Somerville Roberts
-
Patent number: 8580271Abstract: Disclosed are the cloning and expression of a novel antigen of Bartonella henselae. The recombinant polypeptide is found to be highly immunogenic and is useful as a diagnostic test antigen. The polypeptide of the present invention provides the basis of a diagnostic assay that is sensitive, rapid and accurate diagnosis of infection with Bartonella henselae using patient's sera. Disclosed also are the ELISA for both IgG and IgM and allows diagnosis of early and late infection.Type: GrantFiled: August 17, 2012Date of Patent: November 12, 2013Assignee: Medical Diagnostic Laboratories, LLCInventors: John G. Hoey, Lisa P. Huang, Martin E. Adelson, Eli Mordechai
-
Patent number: 8581042Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: June 30, 2011Date of Patent: November 12, 2013Assignees: Novozymes A/S, Novozymes, Inc.Inventors: Marc D. Morant, Shamkant Patkar, Hanshu Ding
-
Patent number: 8574877Abstract: The disclosure relates to methods of producing fatty alcohols from recombinant host cells comprising genes encoding heterologous fatty acyl-CoA reductase (FAR) enzymes. The disclosure further relates to FAR enzymes and functional fragments thereof derived from marine bacterium and particularly marine gamma proteobacterium such as Marinobacter and Oceanobacter; polynucleotides encoding the FAR enzymes and vectors and host cells comprising the same.Type: GrantFiled: June 12, 2012Date of Patent: November 5, 2013Assignee: Codexis, Inc.Inventors: Robert McDaniel, Behnaz Behrouzian, Louis Clark, Douglas A. Hattendorf, Fernando Valle
-
Patent number: 8575426Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: December 17, 2008Date of Patent: November 5, 2013Assignee: Novozymes, Inc.Inventors: Paul Harris, Suchindra Maiyuran, Kimberly Brown
-
Patent number: 8574909Abstract: The invention relates to a strain of the yeast Saccharomyces cerevisiae which, owing to deletion of the genomic sequences, no longer synthesizes hexose transporters and, as a consequence, can no longer grow on substrates with hexoses as the only carbon source, and whose ability of growing on a substrate with a hexose as the only carbon source is restored when it expresses a GLUT4 gene.Type: GrantFiled: April 7, 2006Date of Patent: November 5, 2013Assignee: Sanofi-Aventis Deutschland GmbHInventors: Guenter Mueller, Klaus-Peter Koller, Eckhard Boles, Roman Niedbal, Silke Dlugai
-
Patent number: 8575323Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for transporting sugars across cell membranes using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.Type: GrantFiled: December 20, 2012Date of Patent: November 5, 2013Assignee: Battelle Energy Alliance, LLCInventors: David N. Thompson, William A. Apel, Vicki S. Thompson, David W. Reed, Jeffrey A. Lacey
-
Patent number: 8569455Abstract: A truncated form of ?? chain (e??), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast Pichia pastoris. The recombinant polypeptide spanned 142 amino acid residues from the N-terminal side and included the N-terminal extension region of the soybean alpha? subunit. The e?? polypeptide was purified by conventional biochemical techniques and its potential to modulate the activity of the LDL-receptor was evaluated in a human hepatoma cell line (Hep G2) by monitoring the uptake and degradation of labeled LDL.Type: GrantFiled: June 16, 2010Date of Patent: October 29, 2013Assignee: Indena S.p.A.Inventors: Paolo Morazzoni, Antonella Riva, Cesare Ponzone, Davide Berlanda, Marcello Duranti, Alessandro Consonni
-
Patent number: 8569581Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: September 16, 2010Date of Patent: October 29, 2013Assignee: Novozymes, IncInventors: Suchindra Maiyuran, Randall Kramer, Paul Harris
-
Publication number: 20130280761Abstract: A novel microorganism is provided named Aspergillus saccharolyticus. Further, beta-glucosidase enzymes encoded by said microorganism are provided, and the use thereof in the degradation of lignocellulosic material. Also, host organisms comprising the polypeptides of the invention and/or polynucleotides encoding these are provided. In addition, methods, compositions, and kit-of-parts are provided which comprise any component of the invention, and optionally any additional components.Type: ApplicationFiled: August 1, 2011Publication date: October 24, 2013Applicant: CLEANVANTAGE LLCInventors: Philip Teller, Peter S. Lubeck, Annette Sorensen, Birgitte K. Ahring
-
Patent number: 8563269Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: December 9, 2011Date of Patent: October 22, 2013Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Frederick W. Gluck, Jason Sagert, Patrick Daugherty
-
Patent number: 8557548Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: GrantFiled: March 22, 2013Date of Patent: October 15, 2013Assignee: Wyeth LLCInventors: Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Michael James Flint
-
Patent number: 8557547Abstract: The present invention provides enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention provides a phosphotriesterase enzyme identified from an Agrobacterium radiobacter strain isolated from soil that hydrolyses OP pesticides, and the gene encoding that enzyme. The invention also provides mutants of the identified phosphotriesterase enzyme which have altered substrate specificity. The use of these enzymes in bioremediation strategies is also provided.Type: GrantFiled: October 12, 2012Date of Patent: October 15, 2013Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Irene Horne, Tara Sutherland, Rebecca Harcourt, Robyn Russell, John Oakeshott
-
Patent number: 8551497Abstract: The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a Mycobacteria, for example, Mycobacteria shottsii.Type: GrantFiled: March 30, 2012Date of Patent: October 8, 2013Assignee: University of Georgia Research Foundations, Inc.Inventors: Frederick Quinn, Candace McCombs, Russell K. Karls
-
Publication number: 20130260420Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: January 26, 2012Publication date: October 3, 2013Inventors: Marc D. Morant, Paul Harris
-
Patent number: 8546126Abstract: The present teachings provide methods for increasing protein secretion, e.g., chymosin in filamentous fungi by co-expressing certain chaperone(s) and/or foldase(s). The present teachings also provide filamentous fungi containing certain chaperone(s) and/or foldase(s) and a protein of interest for increased secretion.Type: GrantFiled: March 21, 2008Date of Patent: October 1, 2013Assignee: Danisco US Inc.Inventors: Frits Goedegebuur, Paulien Neefe-Kruithof, Jeffrey P. Pucci, Michael Ward
-
Patent number: 8546118Abstract: This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.Type: GrantFiled: March 7, 2007Date of Patent: October 1, 2013Assignee: Verenium CorporationInventors: David P. Weiner, Lishan Zhao, Peter Luginbuhl, Ellen Burke, Toby Richardson, Paula M. Hicks
-
Patent number: 8546106Abstract: The present invention relates to methods for producing a secreted polypeptide having biological activity, comprising: (a) transforming a fungal host cell with a fusion protein construct encoding a fusion protein, which comprises: (i) a first polynucleotide encoding a signal peptide; (ii) a second polynucleotide encoding at least a catalytic domain of an endoglucanase or a portion thereof; and (iii) a third polynucleotide encoding at least a catalytic domain of a polypeptide having biological activity; wherein the signal peptide and at least the catalytic domain of the endoglucanase increases secretion of the polypeptide having biological activity compared to the absence of at least the catalytic domain of the endoglucanase; (b) cultivating the transformed fungal host cell under conditions suitable for production of the fusion protein; and (c) recovering the fusion protein, a component thereof, or a combination thereof, having biological activity, from the cultivation medium.Type: GrantFiled: July 20, 2007Date of Patent: October 1, 2013Assignee: Novozymes, Inc.Inventor: Sandra Merino
-
Patent number: 8546108Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.Type: GrantFiled: January 24, 2011Date of Patent: October 1, 2013Assignee: Allergan, Inc.Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
-
Patent number: 8541191Abstract: Provided are hydrolases, including lipases, saturases, palmitases and/or stearatases, and polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. Further provided are polypeptides, e.g., enzymes, having a hydrolase activity, e.g., lipases, saturases, palmitases and/or stearatases and methods for preparing low saturate or low trans fat oils, such as low saturate or low trans fat animal or vegetable oils, e.g., soy or canola oils.Type: GrantFiled: April 8, 2011Date of Patent: September 24, 2013Assignee: Bunge Oils, Inc.Inventors: Christopher L. G. Dayton, Tim Hitchman, Katie Kline, Jonathan Lyon, Mark A. Wall, Nelson R. Barton
-
Patent number: 8541203Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.Type: GrantFiled: March 2, 2012Date of Patent: September 24, 2013Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, James W. West, Jason Sagert
-
Publication number: 20130247234Abstract: A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: John MCWHIRTER, Lynn MACDONALD, Andrew J. MURPHY
-
Publication number: 20130243779Abstract: The present invention relates to a protective peptide of Enterococcus faecalis (E. faecalis) or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing an E. faecalis infection; and the use of said peptide for the isolation and/or purification and/or identification of an interaction partner of the peptide.Type: ApplicationFiled: February 4, 2010Publication date: September 19, 2013Applicant: Intercell AGInventors: Eszter Nagy, Beatrice Tschanun, Markus Hanner, Manfred Berger, Andreas Meinke, Alexander Von Gabain, Barbara Murray, Kavindra Singh
-
Publication number: 20130244294Abstract: Methods of manufacturing fuels are provided. These methods use often difficult to process lignocellulosic materials, for example crop residues and grasses. The methods can be readily practiced on a commercial scale in an economically viable manner, in some cases using as feedstocks materials that would otherwise be discarded as waste.Type: ApplicationFiled: May 7, 2013Publication date: September 19, 2013Applicant: XYLECO, INC.Inventors: Marshall MEDOFF, Thomas Craig MASTERMAN
-
Patent number: 8535928Abstract: A novel protease comprising any one of (a) the amino acid sequence of SEQ ID NO: 1, (b) an amino acid sequence having deletion, substitution or addition of one to several amino acids in the amino acid sequence of SEQ ID NO: 1, (c) the amino acid sequence of SEQ ID NO: 3, and (d) an amino acid sequence having deletion, substitution or addition of one to several amino acids in the amino acid sequence of SEQ ID NO: 3, has a high activity under high temperature and high alkaline conditions, a high stability to protein denaturants and surfactants and high effectiveness as a protease used in detergents.Type: GrantFiled: July 30, 2009Date of Patent: September 17, 2013Assignee: Osaka UniversityInventors: Shigenori Kanaya, Tita Foophow, Kazufumi Takano, Yuichi Koga
-
Patent number: 8536315Abstract: The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject.Type: GrantFiled: January 30, 2005Date of Patent: September 17, 2013Assignee: Shire Pharmaceuticals Ireland LimitedInventors: Jens Fogh, Claes Andersson, Cecilia Weigelt, Christer Moller, Pia Hyden
-
Patent number: 8535911Abstract: A progeny cell derived from a parent cell, wherein the progeny cell comprises at least one gene encoding MrgA protein or a functional homologue thereof and/or a DNA segment operably linked with the encoding gene, wherein said gene and/or DNA segment is manipulated with respect to the parent cell; the progeny cell comprises two or more copies of a gene encoding MrgA protein or a functional homologue thereof; or the progeny cell is mutated with respect to the parent cell; whereby the progeny cell produces greater amounts of MrgA protein or a functional homologue thereof than the parent cell.Type: GrantFiled: August 10, 2012Date of Patent: September 17, 2013Assignee: Novosymes A/SInventors: Allan Kent Nielsen, Michael Dolberg Rasmussen
-
Patent number: 8524473Abstract: An improved ethanol production process providing novel stillage treatment is disclosed wherein the stillage is separated into four value added product streams that are subjected to drying conditions reducing or eliminating volatization of any VOC's in the product streams.Type: GrantFiled: July 17, 2012Date of Patent: September 3, 2013Assignee: Little Sioux Corn ProcessorsInventors: Neal Hammond, John Prevost
-
Patent number: 8524471Abstract: The invention concerns a method for the enzymatic treatment of raw polymeric feedstock comprising the following steps: (a) preferably separation of soluble components from the raw polymeric feedstock, (b) treating the raw polymeric feedstock with an enzyme system in order to liberate defined soluble monomeric or oligomeric building blocks from the insoluble raw polymeric feedstock; and (c) separating the defined monomeric or oligomeric building blocks produced in step b) from the remainder of the raw polymeric feedstock. Preferably, the enzyme system used in step b) contains not more than 50%, preferably not more than 20%, more preferably not more than 10%, more preferably not more than 5%, more preferably not more than 2%, more preferably not more than 1% of other enzyme activities apart from the enzyme activity resulting in liberation of said defined monomeric or oligomeric building blocks from the raw polymeric feedstock according to step b).Type: GrantFiled: June 12, 2008Date of Patent: September 3, 2013Assignee: Sud-Chemie IP GmbH & Co. KGInventors: Andre Koltermann, Ulrich Kettling, Thomas Bruck, Markus Rarbach
-
Publication number: 20130219571Abstract: The invention relates to a polypeptide comprising the amino acid sequence set out in SEQ ID NO: 2 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1, or a variant polypeptide or variant polynucleotide thereof, wherein the variant polypeptide has at least 73% sequence identity with the sequence set out in SEQ ID NO: 2 or the variant polynucleotide encodes a polypeptide that has at least 73% sequence identity with the sequence set out in SEQ ID NO: 2. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional polypeptide and functional equivalents of the gene or the amino acid sequence. The invention also relates to methods for using the polypeptide in industrial processes. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins.Type: ApplicationFiled: June 23, 2011Publication date: August 22, 2013Applicant: DSM IP ASSETS B.V.Inventors: Margot Elisabeth Francoise Schoonneveld-Bergmans, Wilbert Herman Marie Heijne, Monica D. Vlasie, Robbertus Antonius Damveld
-
Patent number: 8512703Abstract: The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations.Type: GrantFiled: July 24, 2008Date of Patent: August 20, 2013Assignee: Areta International S.R.L.Inventors: Riccardo Dolcetti, Massimo Guidoboni, Valli De Re, Daniela Gasparotto, Sonia Castiglioni, Maria Luisa Nolli
-
Patent number: 8507238Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: October 8, 2012Date of Patent: August 13, 2013Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: RE44512Abstract: The present invention provides a method for controlling the partitioning of a recombinant protein between the supernatant and the periplasm in E. coli host cell cultures wherein expression of the recombinant protein by said cells is under the control of an inducible system, which method comprises: a) providing an E. coli host cell culture b) changing the growth rate of the E. coli host cells c) inducing expression of the recombinant protein wherein steps (b) and (c) can be performed in any order or simultaneously; and subsequently d) determining the yield of recombinant protein in the culture supernatant and the E. coli host cell periplasm e) comparing the yield determined in step (d) with the yield determined when at least one other growth rate has been used in step (b) f) selecting a growth rate from the comparison made in step (e) in which the partitioning of the recombinant protein between the supernatant and the periplasm is most suited to the primary recovery of the recombinant protein.Type: GrantFiled: September 2, 2004Date of Patent: October 1, 2013Assignee: UCB Pharma S.A.Inventors: David John Glover, Mukesh Sehdev, Dominic Gambier Reeks